Remote Care Technology Top Pick for ’23 Impact | Managed Healthcare Executive® State of the Industry Survey
In the political and policy arena, respondents see implementation of the Inflation Recovery Act as having a major effect this year.
Healthcare technology is teeming with possibilities for improving the cost and delivery of healthcare. Precision medicine, artificial intelligence, prescription digital therapeutics — they are all being talked about as powerful waves that will shape the future contours of U.S. healthcare.
But as far as having an effect this year, remote are technologies was the top pick among the respondents to the Managed Healthcare Executive® annual State of the Industry survey. A solid majority — 56% — of the approximately 450 respondents to the survey indicated that remote care technology would be among the healthcare technology developments to have the biggest effect on the cost and delivery of healthcare in 2023.
One-third (33%) of the respondents picked interoperability. A similar proportion (32%) picked prescription digital therapeutics. The respondents were instructed to pick more than one of the choices, which also included gene therapy,precision medicine and artificial intelligence
In the policy and political arena, implementation of the healthcare provisions of the Inflation Recovery Act was the top pick for making a splash this year: 54% of the respondents picked it in response a question which policy and political developments will have the biggest effect this year. Perhaps the most important provision of the law is the one that empowers CMS to negotiate drug prices. According to a timeline that CMS issued last week, CMS will publish a list of the first 10 drugs for which it will negotiate a price on Sept. 1, 2023, but it won’t be until 2026 that the negotiated prices will go into effect.
A little more than one-third (35%) respondents picked the end of the COVID-19 public health emergency as having a large effect this year and less than one-third (31%) picked the end of continuous Medicaid enrollment.
The survey was conducted online in November and early December. Medical Economics® assisted with its distribution,
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
Five-Year Data Reinforce Survival Benefit of Opdivo/Yervoy in Advanced Lung Cancer
November 13th 2024Patients with metastatic non-small cell lung cancer, even those with brain metastases, experienced improved longer-term clinical outcomes while on the Opdivo/Yervoy combination compared with those patients receiving chemotherapy alone.
Read More
